In this sense, hyaluronidase PEGPH20 in combination with eribulin versus eribulin alone showed in phase II clinical trial (NCT02753595) improved antitumor effects in subjects with HER2-negative breast cancer [201]. The gene discussed is ERBB2; the disease is breast carcinoma.